2 results
Approved WMORecruiting
Primary: To assess the efficacy of treatment with 300 mg or 600 mg of intravenous (IV) zanamivir twice daily compared to 75 mg of oral oseltamivir twice daily on time to clinical response. Secondary: reduction in viral load from nasopharyngeal swabs…
Approved WMORecruiting
Primary Objective is to test the feasibility of a strategy in which patient preference, after a short exposure to treatment options, determines the choice for a specific phosphate binder and whether this strategy will improve patient*s satisfaction.…